|
1）厚生労働省健康局総務課生活習慣病対策室．糖尿病の状況．平成19年国民健康・栄養調査報告（平成22年3月）．2010. p.44-55
|
|
|
|
|
2）日本糖尿病学会，編．科学的根拠に基づく糖尿病診療ガイドライン2013. 東京: 南江堂; 2013
|
|
|
|
|
|
3）日本糖尿病学会，編．糖尿病治療ガイド2012-2013 血糖コントロール目標改訂版. 東京: 文光堂; 2013
|
|
|
|
|
|
4）浜野久美子. 糖尿病治療における低血糖・体重増加の問題点. Prog Med. 2010; 30: 369-73
|
|
|
|
|
5）大久保博史，大野晴也，浅野知一郎. 糖輸送体. G I Research. 2011; 19: 412-7
|
|
|
|
|
|
6）Hediger MA, Coady MJ, Ikeda TS, et al. Expression cloning and cDNA sequencing of the Na+/glucose cotransporter. Nature. 1987; 330: 379-81
|
|
|
|
|
7）前川 聡，柏木厚典. 新しい経口抗糖尿病治療薬：SGLT2阻害薬. 月刊糖尿病．2012; 4: 113-20
|
|
|
|
|
|
8）大谷裕一郎，浅野知一郎. SGLT2阻害薬. Current Therapy. 2012; 30: 80-5
|
|
|
|
|
|
9）Turk E, Kerner CJ, Lostao MP, et al. Membrane topology of the human Na+/glucose cotransporter SGLT1. J Biol Chem. 1996; 271: 1925-34
|
|
|
|
|
|
10）Mitrakou A. Kidney: its impact on glucose homeostasis and hormonal regulation. Diabetes Res Clin Pract. 2011; 93 Suppl 1: S66-72
|
|
|
|
|
|
11）Ehrenkranz JR, Lewis NG, Kahn CR, et al. Phlorizin: a review. Diabetes Metab Res Rev. 2005; 21: 31-8
|
|
|
|
|
|
12）Alvarado F, Crane RK. Pholorizin as a competitive inhibitor of the active transport of sugars by hamster small intestine, in vitro. Biochim Biophys Acta. 1962; 56: 170-2
|
|
|
|
|
|
13）Oku A, Ueta K, Arakawa K, et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999; 48: 1794-800
|
|
|
|
|
|
14）Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action. J Diabetes Investig. 2014; 5: 265-75
|
|
|
|
|
|
15）Mackenzie B, Loo DD, Panayotova-Heiermann M, et al. Biophysical characteristics of the pig kidney Na+/glucose cotransporter SGLT2 reveal a common mechanism for SGLT1 and SGLT2. J Biol Chem. 1996; 271: 32678-83
|
|
|
|
|
|
16）Suzuki M, Takeda M, Kito A, et al. Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr Diabetes. 2014; 4: e125
|
|
|
|
|
|
17）Kaku K, Watada H, Iwamoto Y, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014; 13: 65
|
|
|
|
|
|
18）Tanizawa Y, Kaku K, Araki E, et al. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials. Expert Opin Pharmacother. 2014; 15: 749-66
|
|
|
|
|
|
19）Inagaki N, Kondo K, Yoshinari T, et al. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab. 2013; 15: 1136-45
|
|
|
|
|
|
20）Kaku K, Inoue S, Matsuoka O, et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2013; 15: 432-40
|
|
|
|
|
|
21）Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013; 36: 2508-15
|
|
|
|
|
|
22）Nauck MA, Del Prato S, Durán-García S, et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab. 2014; 16: 1111-20
|
|
|
|
|
|
23）Wilding JP, Norwood P, Tʼjoen C, et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009; 32: 1656-62
|
|
|
|
|
|
24）日本糖尿病学会．SGLT2阻害薬の適正使用に関する委員会. http://www.jds.or.jp/common/fckeditor/editor/filemanager/connectors/php/transfer.php?file=/uid000025_7265636F6D6D656E646174696F6E5F53474C54322E706466
|
|
|
|
|